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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is 
tanezumab more effective than a placebo in reducing pain in patients with osteoarthritis?”  
 
 
STUDY DESIGN: Review of three randomized, double-blind, placebo controlled trials from 
2012 to 2015. 
 
 
DATA SOURCES: Three double-blind randomized clinical trials (RCTs) were found using 
PubMed, and selected based on outcomes measured and relevance to the objective.  
 
 
OUTCOMES MEASURED: Clinical outcomes of knee and hip osteoarthritis pain were 
measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
pain scale to assess pain before and after treatment with tanezumab and comparison.   
 
 
RESULTS: All three randomized studies showed treatment with tanezumab was statistically 
significant (p-value ≤0.001) for improvement in pain at 16 weeks after injections. An adverse 
event was reported in each study.    
 
 
CONCLUSIONS: Based on the studies reviewed in this paper, the evidence suggest the efficacy 
of tanezumab for hip and knee osteoarthritis pain is conclusive as an effective treatment.  
 
 
KEY WORDS: Osteoarthritis, tanezumab, knee pain, hip pain  
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INTRODUCTION 
Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people 
worldwide. OA is a slowly progressive joint disease typically seen in middle-age to elderly 
individuals.1 It causes debilitating pain and can lead to a loss of function in mobility, which 
eventually decreases an individual’s quality of life. OA is characterized by the breakdown of 
cartilage on the ends of bones, bony changes to the joints, deterioration of tendons and ligaments, 
and various degrees of inflammation of the joint lining.1 At least 15 percent of all adults over the 
age of 60 are believed to suffer from this disorder with females having greater prevalence of 
osteoarthritis than males.2 While the definitive treatment for OA is total joint replacement, 
patients seek less invasive forms of treatment to relieve their pain, improve their function, and 
prolong their quality of life. This paper evaluates three randomized controlled trials (RCTs) 
comparing the efficacy of tanezumab as an oral medication for reducing pain in patients with 
osteoarthritis. 
Osteoarthritis ranks fifth among all forms of disability worldwide.2 Hip and knee 
osteoarthritis represent a significant cause of that disability.2 Osteoarthritis pain, swelling, and 
stiffness make it difficult to perform ordinary tasks at work or at home. When the lower body 
joints are affected, activities such as walking, climbing stairs and lifting objects become difficult. 
Medical costs for adults with osteoarthritis are approximately $2,079 per person per year.3 In 
2010, there were 21.7 million ambulatory care visits and over 6.7 million inpatient 
hospitalizations for people with OA.3 These statistics demonstrate the importance of providing 
pain relief to patients with OA in efforts to decrease health care visits and health care costs.  
  Long-term management of osteoarthritis requires a multidisciplinary approach, including 
the help from physician assistants, to manage symptoms, improve joint mobility and flexibility, 
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and maintain a healthy weight. OA can affect any joint, but it occurs most often in knees, hips, 
lower back and neck, small joints of the fingers and the bases of the thumb and great toe.4 
Several specific risk factors have been identified including obesity and metabolic disease, age, 
sex, nutrition, smoking, bone density and muscle function.4 Aside from non-medical treatments 
including weight loss, physical therapy, assistive devices, and dietary supplements, there are very 
few medications that can be used in the management of this disease due to their association with 
multiple side effects. These medications include acetaminophen, NSAIDs, topical NSAIDs, 
including capsaicin cream and diclofenac gel, opioids, and joint injections with corticosteroids or 
hyaluronic acid. Thus, when lifestyle modifications are ineffective and patients have exhausted 
all the recommended medications, their last option is surgery and not all elderly patients are 
suitable for that option. Therefore, this paper will be reviewing tanezumab as an alternative 
medication. Tanezumab is a humanized monoclonal antibody that targets, binds to, and inhibits 
nerve growth factor (NGF).5 NGF increases in the body when there is injury, inflammation or 
chronic pain. Tanezumab inhibits the NGF and thereby stops pain signals from reaching the 
spinal cord and brain.5 This mechanism is different from that of conventional opioids and 
analgesics.5  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not tanezumab is 
more effective than a placebo in reducing pain in patients with osteoarthritis.  
METHODS 
Three double-blind randomized clinical trials (RCTs) were selected for this review. These 
studies consisted of males and females with hip or knee osteoarthritis pain. The intervention was 
tanezumab 10 mg IV, and comparisons were done between the treatment group receiving 
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tanezumab and the experimental group who received a comparison drug. The studies measured 
the efficacy of tanezumab on reducing knee or hip osteoarthritis pain using the Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC) pain scale.  
All articles were published in peer-reviewed journals between 2012 and 2015, and they 
were published in English. Key words used during research via PubMed were “tanezumab,” 
“osteoarthritis,” “knee pain,” and “hip pain.” The articles chosen were based on their relevance 
to the clinical question and on importance of outcome to the patient (patient oriented evidence 
that matters). Inclusion criteria for the studies selected required the use of randomized control 
double-blinded trials and studies published after 2006. Exclusion criteria involved the use of 
DOE outcome measures. The statistics reported in the selected studies were p-values. Table 1 
represents the demographics and characteristics of the included studies.   
Table 1- Demographics and Characteristics of Included Studies  
Study Type # Pts  Age 
(yrs) 
Inclusion Criteria Exclusion criteria  W/D Interventions 
Brown et 
al.5 
(2013) 
RCT 621 32-
87 
-Unwillingness/inability to take 
nonopiate pain medications, 
inadequate pain relief from 
nonopiate pain medications, or 
candidacy for intraarticular 
injections or total hip joint 
replacement. 
-WOMAC score of ³ 4 at screening 
and ³ 5 at baseline, and an increase 
of ³ 1 from screening to baseline if 
they had been regularly taking pain 
medications prior to screening and 
were required to wash out prior to 
baseline.   
-Pregnant or intent to become 
pregnant during the study 
-BMI >39 kg/m2 
-Had moderate to severe pain 
other than that related to OA 
-Had any condition that could 
confound OA pain assessment 
-Had significant cardiac, 
neurologic, or psychiatric 
conditions.  
10 tanezumab 
10 mg IV 
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OUTCOMES MEASURED  
 
The primary outcome measured in the selected studies were based on pain assessment 
before and after treatment with tanezumab or comparison drug using the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) pain scale. All three studies used the 
WOMAC pain scale for evaluation of pain at baseline (study day 1) and at week 16. This was 
measured using a numerical rating scale of 0 to 10, in which increasing scores represent greater 
pain intensity. All three studies provided an adverse event as dichotomous data, reporting the 
number of patients in both experimental and comparison groups who experienced paresthesias.  
RESULTS 
Brown et 
al.6 
(2012) 
RCT 690 21-
92 
-X-ray taken within the previous 12 
months 
-Kellgren-Lawrence X-ray grade ³ 
2 
-At least 1 of the following: 
unwillingness or inability to take 
nonopiate medications, inadequate 
pain relief from nonopiate 
medications, candidacy for 
intraarticular injections, knee 
arthroplasty, or knee replacement 
surgery. 
-WOMAC score in the index knee 
³ 4 at screening and ³ 5 at baseline, 
and in patients who washed out of 
regularly taken pain medications 
after screening, an increase ³ 1 
from screening to baseline.  
-Patients who were pregnant or 
intended to become pregnant 
during the study 
-BMI > 39 kg/m2 
-Patient who had pain 
syndromes that could confound 
assessment of pain from OA 
(e.g. fibromyalgia, systemic 
lupus erythematosus), or had 
significant cardiac, neurologic, 
or psychological conditions  
 
72 tanezumab 
10 mg IV 
 
Schnitzer 
et al.7 
RCT 2700 20-
93 
-Kellgren-Lawrence grade ³ 2  
-BMI £ 39 kg/m2 
-Taking stable oral NSAID 
(naproxen 500-1000 mg/day or 
celecoxib 200 mg/day for minimum 
of 30 days prior to screening, and 
experiencing at least some 
analgesic benefit  
-WOMAC score ³ 4 at screening  
-Have at least 70% compliance with 
study-supplied oral NSAID 
treatment over at least 14 days 
directly prior to baseline 
 
-“Similar to other tanezumab 
trials”  
-Any abnormality that would 
preclude continued NSAID 
therapy, including country-
specific restrictive exclusion 
criteria for naproxen or 
celecoxib use in subjects with 
cardiac disease 
 
376 tanezumab 
10 mg IV 
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 In the study by Brown et al.5 (2013), efficacy data was based on a modified ITT 
population (611 patients), which was defined as all patients who were randomized and treated 
with at least 1 dose of study medication, but which excluded all patients from 1 study site 
because of significant deviations from good clinical practice and 1 additional patient from 
another site due to possible unblinding.5 Patients were randomized equally to receive intravenous 
tanezumab 10 mg or a comparison drug. For both groups, study medication was administered at 
8-week intervals, and efficacy data was measured at baseline and at week 16. Patient 
demographics and baseline characteristics were similar across treatment groups, as shown above 
in Table 1.   
At the conclusion of the study, the WOMAC pain scale changed from baseline to week 
16, producing statistically significant improvements (p ≤0.001) relative to the comparison. At the 
start of the study (study day 1), both the experimental group and comparison group had an 
average WOMAC pain scale score of 7.3. By week 16, the mean change from baseline was -1.62 
for the comparison group and -3.37 for the experimental group, producing a p-value of ≤0.001 
for the experimental group. This is demonstrated below in Table 2.   
Table 2 – Statistical outcome measures for patients with osteoarthritic hip pain  
 Outcome 
measured 
Scoring 
system 
Baseline  Mean change 
from baseline 
P-value 
Comparison Pain WOMAC 7.3 -1.62 ≤0.001 
Tanezumab Pain WOMAC 7.3 -3.37 
 
In this study safety data was based on the ITT population, which was defined as all 
patients who were randomized and treated with at least 1 dose of study medication.5 Brown et 
al.5 (2013) demonstrated that 5.1% of the patients in the experimental group experienced 
paresthesias while 3.9% in the comparison group. This correlates with a NNH of 83, concluding 
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that for every 83 people treated with tanezumab, 1 more person will experience paresthesias 
when compared to the control (Table 5 below).   
 In the study by Brown et al.6 (2012), 690 individuals (ITT population) received study 
medication, however a modified intent-to-treat (mITT) population of 618 was established. mITT 
population was defined as all patients randomized and treated with ≥ 1 dose of study medication 
and excluding patients from any study site that was found to have significant deviation from 
good clinical practices or patients from whom there were possible breaches in study blinding. 6 
Results from analyses performed using the ITT population were consistent with those obtained 
using the mITT population and led to the same conclusions.6 Patients received blinded study 
medication at 8 week intervals on 3 occasions: baseline (study day 1), week 8 (study day 57), 
and week 16 (study day 113). Primary efficacy results were measured at week 16.  
 At the completion of this study, treatment with tanezumab produced significant 
improvement in pain from baseline to week 16 in primary efficacy measures. Baseline scores for 
the comparison group and experimental group were 7.1 and 7.0 respectively. The mean change 
from baseline in the comparison group was approximately -2.5, and in the experimental group it 
was approximately -3.5, based on the graphical data provided in the study (Table 3). Treatment 
with tanezumab had a significant improvement in the primary WOMAC pain scale compared to 
the control with a p-value of ≤0.001.   
Table 3 - Statistical outcome measures for patients with osteoarthritic knee pain 
 Outcome 
measured 
Scoring 
system 
Baseline  Mean change 
from baseline 
P-value 
Comparison Pain WOMAC 7.1 -2.5 ≤0.001 
Tanezumab Pain WOMAC 7.0 -3.5 
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 Brown et al.6 (2012) provided dichotomous data to calculate NNH on the adverse event 
of paresthesias due to the treatment. The study demonstrated that 5.1% of the patients in the 
experimental group experienced adverse events while 1.7% in the comparison group. This 
correlates with a NNH of 29, concluding that for every 29 people treated with tanezumab, 1 more 
person will experience an adverse event when compared to control (Table 5 below).   
 In the study by Schnitzer et al.7, participants were randomized by a computer-generated 
randomization code to either the tanezumab group or the comparison group. Tanezumab or 
matching comparison was given intravenously at baseline and every 8 weeks for a total of 7 
administrations. Efficacy and safety were assessed using ITT populations and results were 
measured on week 16.  
 At the completion of this study, it was determined that at the 16-week mark tanezumab 
resulted in significant greater mean improvement of WOMAC pain compared to the comparison 
drug with a p-value of ≤0.001. The baseline score for both groups was 6.3, with the mean change 
from baseline being -1.5 for the comparison group and -2.25 for the experimental group. This 
correlates with a p-value ≤0.001 for the experimental group versus the comparison group.  
Table 4 - Statistical outcome measures for patients with osteoarthritic knee and hip pain 
 Outcome 
measured 
Scoring 
system 
Baseline  Mean change 
from baseline 
P-value 
Comparison Pain WOMAC 6.3 -1.5 ≤0.001 
Tanezumab Pain WOMAC 6.3 -2.25 
 
 Schnitzer et al.7 demonstrated that 7.2% of the patients in the experimental group 
experienced an adverse event while 3.1% in the control group. This correlates to a NNH of 24, 
concluding that for every 24 people being treated with tanezumab, 1 more person will experience 
an adverse event of paresthesias when compared to control (Table 5).   
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Table 5 – Statistical data on the adverse event in each study  
AE: Paresthesias Control 
event rate 
(%) 
Experimental 
event rate 
(%)  
Relative 
risk 
increase 
(RRI) 
Absolute 
risk 
increase 
(ARI) 
Number 
needed to 
harm 
(NNH) 
Brown et al.5 (2013) 3.9 5.1 0.31 0.012 83 patients 
Brown et al.6 (2012) 1.7 5.1 2 0.034 29 patients 
Schnitzer et al.7 3.1 7.2 1.3 0.041 24 patients 
 
DISCUSSION 
 The results above demonstrate a benefit to the use of tanezumab in patients with knee or 
hip osteoarthritis pain. The p-value for the treatment of tanezumab in all three studies are ≤0.001 
indicating that there is significant improvement in pain after using tanezumab. The NNH for 
Brown et al.5 (2013), Brown et al.6 (2012) and Schnitzer et al.7 are 83, 29 and 24 respectively, 
indicating that a large number of people can be treated with tanezumab before the adverse event 
of paresthesias occur (Table 5). Even so, the adverse events reported were not consistent with 
progressively worsening peripheral nerve damage with tanezumab treatment leading to 
peripheral polyneuropathy. Evidence from neurologic evaluations of patients reporting adverse 
events revealed symptoms were associated with focal mononeuropathy, such as carpal tunnel 
syndrome, that was preexisting or possibly aggravated by tanezumab treatment.5,6,7   
There is a limitation noted in the study by Schnitzer et al.7 that should be discussed. 
During this study, the FDA placed all clinical studies of tanezumab on clinical hold due to 
unexpected adverse events initially described as osteonecrosis that required total joint 
replacement. The primary efficacy objectives of this study were not impacted by the clinical 
hold, however assessment of long-term efficacy (beyond 16 weeks) was limited.7   
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It is important to mention that the title of this systemic review is incorrect. The word 
“placebo” was used in the title of this review when in fact tanezumab has been compared to both 
placebos and an NSAID in the RCTs selected for this review. In the studies by Brown et al. 
(2012 and 2013) the efficacy of tanezumab for reducing pain is compared to placebos. In the 
study by Schnitzer et al. the efficacy of tanezumab for reducing pain is compared to Naproxen. 
Therefore, the title of this review is incorrect and must be corrected and generalized so it states 
that tanezumab has been compared to comparison drugs.  
CONCLUSION 
 The results of this systematic review suggest that tanezumab is more effective than 
comparison drugs in reducing pain in patients with osteoarthritis of the knee or hip. The p-value 
in each study revealed statistical significance in the use of tanezumab when compared to the 
comparison drugs, and the NNH calculated in each study demonstrated little adverse events. 
However, paresthesias can be relatively bothersome to live with as an adverse event from 
treatment with tanezumab. Therefore, future study populations should consist of patients with 
little to no medical histories that could predispose those patients to findings suggestive of 
neuropathy during the study. This could help determine if the adverse event of paresthesias is 
related to treatment with tanezumab.  
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